Huys I[au] - Search Results

Year	Number of Results
1993	1
2000	1
2001	2
2002	2
2003	3
2004	6
2009	1
2010	1
2011	2
2012	5
2013	8
2014	5
2015	11
2016	8
2017	14
2018	8
2019	17
2020	34
2021	36
2022	6

1

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review.

Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I. Barbier L, et al. Among authors: huys i. Clin Pharmacol Ther. 2020 Oct;108(4):734-755. doi: 10.1002/cpt.1836. Epub 2020 Apr 30. Clin Pharmacol Ther. 2020. PMID: 32236956 Free PMC article.

2

The Magistral Phage.

Pirnay JP, Verbeken G, Ceyssens PJ, Huys I, De Vos D, Ameloot C, Fauconnier A. Pirnay JP, et al. Among authors: huys i. Viruses. 2018 Feb 6;10(2):64. doi: 10.3390/v10020064. Viruses. 2018. PMID: 29415431 Free PMC article. Review.

3

R&D Costs of New Medicines: A Landscape Analysis.

Simoens S, Huys I. Simoens S, et al. Among authors: huys i. Front Med (Lausanne). 2021 Oct 26;8:760762. doi: 10.3389/fmed.2021.760762. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34765624 Free PMC article. Review.

4

Repurposing drugs in oncology: From candidate selection to clinical adoption.

Pantziarka P, Verbaanderd C, Huys I, Bouche G, Meheus L. Pantziarka P, et al. Among authors: huys i. Semin Cancer Biol. 2021 Jan;68:186-191. doi: 10.1016/j.semcancer.2020.01.008. Epub 2020 Jan 23. Semin Cancer Biol. 2021. PMID: 31982510 Review.

5

Biosimilars in Belgium: a proposal for a more competitive market.

Moorkens E, Vulto AG, Huys I. Moorkens E, et al. Among authors: huys i. Acta Clin Belg. 2021 Dec;76(6):441-452. doi: 10.1080/17843286.2020.1761690. Epub 2020 May 13. Acta Clin Belg. 2021. PMID: 32400319 Review.

6

The necessity for a European definition of drug shortages.

De Weerdt E, Simoens S, Casteels M, Huys I. De Weerdt E, et al. Among authors: huys i. Int J Pharm Pract. 2018 Aug;26(4):289-290. doi: 10.1111/ijpp.12459. Int J Pharm Pract. 2018. PMID: 29972611 No abstract available.

7

Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study.

Janssens R, Lang T, Vallejo A, Galinsky J, Plate A, Morgan K, Cabezudo E, Silvennoinen R, Coriu D, Badelita S, Irimia R, Anttonen M, Manninen RL, Schoefs E, Vandebroek M, Vanhellemont A, Delforge M, Stevens H, Simoens S, Huys I. Janssens R, et al. Among authors: huys i. Front Med (Lausanne). 2021 Jul 6;8:686165. doi: 10.3389/fmed.2021.686165. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34295912 Free PMC article.

8

European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption.

Barbier L, Simoens S, Vulto AG, Huys I. Barbier L, et al. Among authors: huys i. BioDrugs. 2020 Dec;34(6):783-796. doi: 10.1007/s40259-020-00452-9. BioDrugs. 2020. PMID: 33141421 Free PMC article. Review.

9

Informing Patients about Biosimilar Medicines: The Role of European Patient Associations.

Vandenplas Y, Simoens S, Van Wilder P, Vulto AG, Huys I. Vandenplas Y, et al. Among authors: huys i. Pharmaceuticals (Basel). 2021 Feb 4;14(2):117. doi: 10.3390/ph14020117. Pharmaceuticals (Basel). 2021. PMID: 33557030 Free PMC article. Review.

10

Innovative Approaches to Increase Access to Medicines in Developing Countries.

Stevens H, Huys I. Stevens H, et al. Among authors: huys i. Front Med (Lausanne). 2017 Dec 7;4:218. doi: 10.3389/fmed.2017.00218. eCollection 2017. Front Med (Lausanne). 2017. PMID: 29270407 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results